These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 1450448)
1. Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow. Berger DP; Winterhalter BR; Dengler WA; Fiebig HH Anticancer Drugs; 1992 Oct; 3(5):531-9. PubMed ID: 1450448 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line. Pacheco DY; Stratton NK; Gibson NW Cancer Res; 1989 Sep; 49(18):5108-10. PubMed ID: 2766282 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of toxicity of hepsulfam in human tumor cell lines. Pacheco DY; Cook C; Hincks JR; Gibson NW Cancer Res; 1990 Dec; 50(23):7555-8. PubMed ID: 2253204 [TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units. Marshall MV; Marshall MH; Degen DR; Roodman GD; Kuhn JG; Ross ME; Von Hoff DD Stem Cells; 1993 Jan; 11(1):62-9. PubMed ID: 8457783 [TBL] [Abstract][Full Text] [Related]
5. Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance. Armstrong DK; Gordon GB; Hilton J; Streeper RT; Colvin OM; Davidson NE Cancer Res; 1992 Mar; 52(6):1416-21. PubMed ID: 1540950 [TBL] [Abstract][Full Text] [Related]
6. In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients. Hincks JR; Adlakha A; Cook CA; Johnson CS; Furmanski P; Gibson NW Cancer Res; 1990 Dec; 50(23):7559-63. PubMed ID: 2253205 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of dimethylaminosulfonates of alkane diols as a novel group of anticancer agents. Sanyal U; Nanda R; Samanta S; Pain A; Dutta S; Verma AS; Rider BJ; Agrawal KC Cancer Lett; 2000 Jul; 155(1):89-97. PubMed ID: 10814884 [TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of hepsulfam (NSC 329680). Hendricks CB; Grochow LB; Rowinsky EK; Forastiere AA; McGuire WP; Ettinger DS; Sartorius S; Lubejko B; Donehower RC Cancer Res; 1991 Nov; 51(21):5781-5. PubMed ID: 1933848 [TBL] [Abstract][Full Text] [Related]
9. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development. Fiebig HH; Schmid JR; Bieser W; Henss H; Lohr GW Eur J Cancer Clin Oncol; 1987 Jul; 23(7):937-48. PubMed ID: 3665999 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow. Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373 [TBL] [Abstract][Full Text] [Related]
11. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening. Berger DP; Henss H; Winterhalter BR; Fiebig HH Ann Oncol; 1990 Sep; 1(5):333-41. PubMed ID: 2261375 [TBL] [Abstract][Full Text] [Related]
12. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139 [TBL] [Abstract][Full Text] [Related]
13. Hepsulfam induced DNA adducts and its excision repair by bacterial and mammalian 3-methyladenine DNA glycosylases. Je KH; Son JK; O'Connor TR; Lee CS Mol Cells; 1998 Dec; 8(6):691-7. PubMed ID: 9895121 [TBL] [Abstract][Full Text] [Related]
14. Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Du DL; Volpe DA; Grieshaber CK; Murphy MJ Invest New Drugs; 1991 May; 9(2):149-57. PubMed ID: 1874599 [TBL] [Abstract][Full Text] [Related]
15. A phase I clinical and pharmacokinetic trial of hepsulfam. Ravdin PM; Havlin KA; Marshall MV; Brown TD; Koeller JM; Kuhn JG; Rodriguez G; Von Hoff DD Cancer Res; 1991 Dec; 51(23 Pt 1):6268-72. PubMed ID: 1933887 [TBL] [Abstract][Full Text] [Related]
16. Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons. Marshall MV; Carey KD; Von Hoff DD; Kuhn JG Invest New Drugs; 1995; 13(1):33-6. PubMed ID: 7499105 [TBL] [Abstract][Full Text] [Related]
17. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683 [TBL] [Abstract][Full Text] [Related]
19. Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine. Roosen N; Doz F; Yeomans KL; Dougherty DV; Rosenblum ML Cancer Chemother Pharmacol; 1994; 34(5):385-92. PubMed ID: 7520843 [TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]